The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Normalip     ethyl2-(4-chlorophenoxy)-2- methyl-propanoate

Synonyms: Atromid, Miscleron, Miskleron, Athromidin, clofibrate, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Miscleron


Psychiatry related information on Miscleron


High impact information on Miscleron

  • We studied the effect of th bite acid sequestrant colestipol, alone and in combination with clofibrate or niacin, in patients with heterozygous familial hypercholesterolemia who were given a diet low in cholesterol and saturated fat [9].
  • Low pretreatment lipoprotein-lipase activity in adipose-tissue specimens and postheparin plasma increased to normal with clofibrate, whereas low hepatic triglyceride lipase activity did not change [1].
  • Synaptic transmission is partially impaired in syd-2 mutants. syd-2 encodes a member of the liprin (for LAR-interacting protein) family of proteins which interact with LAR-type (for leukocyte common antigen related) receptor proteins with tyrosine phosphatase activity (RPTPs) [10].
  • Unique, spindle-shaped particles (phi bodies) and rods with peroxidatic activity are found in certain epithelial cells of normal mice, clofibrate-fed rats, and in leukemic leukocytes [11].
  • These two hypolipidemic peroxisome proliferators are structurally different from ethyl a-p-chlorophenozyisobutyrate (clofibrate) and other hypolipidemic, arylocyisobutyrate derivatives which cause hepatic peroxisome proliferation [12].

Chemical compound and disease context of Miscleron


Biological context of Miscleron


Anatomical context of Miscleron


Associations of Miscleron with other chemical compounds


Gene context of Miscleron


Analytical, diagnostic and therapeutic context of Miscleron


  1. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. Goldberg, A.P., Applebaum-Bowden, D.M., Bierman, E.L., Hazzard, W.R., Haas, L.B., Sherrard, D.J., Brunzell, J.D., Huttunen, J.K., Ehnholm, C., Nikkila, E.A. N. Engl. J. Med. (1979) [Pubmed]
  2. Clofibrate effect on alkaline phosphatase in renal failure. Kijima, Y., Sasaoka, T., Kanayama, M., Kubota, S. N. Engl. J. Med. (1977) [Pubmed]
  3. Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy. Smals, A.G., Beex, L.V., Kloppenborg, P.W. N. Engl. J. Med. (1977) [Pubmed]
  4. Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. de Groote, M.A., Martin, M.A., Densen, P., Pfaller, M.A., Wenzel, R.P. JAMA (1989) [Pubmed]
  5. Enhancement of voluntary alcohol consumption in rats by clofibrate feeding. Schlicht, I. Alcohol (1987) [Pubmed]
  6. Prevention of atherosclerosis in childhood. Cresanta, J.L., Burke, G.L., Downey, A.M., Freedman, D.S., Berenson, G.S. Pediatr. Clin. North Am. (1986) [Pubmed]
  7. Comparison of clofibrate and chlorpropamide in vasopressin-responsive diabetes insipidus. Thompson, P., Earll, J.M., Schaaf, M. Metab. Clin. Exp. (1977) [Pubmed]
  8. Effect of clofibrate, cholestyramine, cholesterol and feeding pattern on the diurnal variation of cholesterol 7 alpha-hydroxylation in swine. Li, J.R., Kim, D.N., Lee, K.T., Reiner, J.M., Thomas, W.A. Exp. Mol. Pathol. (1980) [Pubmed]
  9. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. Kane, J.P., Malloy, M.J., Tun, P., Phillips, N.R., Freedman, D.D., Williams, M.L., Rowe, J.S., Havel, R.J. N. Engl. J. Med. (1981) [Pubmed]
  10. The liprin protein SYD-2 regulates the differentiation of presynaptic termini in C. elegans. Zhen, M., Jin, Y. Nature (1999) [Pubmed]
  11. Phi bodies: peroxidatic particles that produce crystalloidal cellular inclusions. Hanker, J.S., Romanovicz, D.K. Science (1977) [Pubmed]
  12. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Reddy, J.K., Krishnakantha, T.P. Science (1975) [Pubmed]
  13. Hepatotoxicity of germander in mice. Loeper, J., Descatoire, V., Letteron, P., Moulis, C., Degott, C., Dansette, P., Fau, D., Pessayre, D. Gastroenterology (1994) [Pubmed]
  14. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Laurin, J., Lindor, K.D., Crippin, J.S., Gossard, A., Gores, G.J., Ludwig, J., Rakela, J., McGill, D.B. Hepatology (1996) [Pubmed]
  15. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Brown, W.V. Am. J. Med. (1987) [Pubmed]
  16. Are agents affecting platelet functions clinically useful? Verstraete, M. Am. J. Med. (1976) [Pubmed]
  17. Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action. D'Costa, M.A., Angel, A. J. Clin. Invest. (1975) [Pubmed]
  18. Response of microbodies in Morris hepatoma 9618A to clofibrate. Tsukada, H., Mochizuki, Y., Itabashi, M., Gotoh, M., Morris, H.P. J. Natl. Cancer Inst. (1975) [Pubmed]
  19. Familial apolipoprotein E deficiency. Schaefer, E.J., Gregg, R.E., Ghiselli, G., Forte, T.M., Ordovas, J.M., Zech, L.A., Brewer, H.B. J. Clin. Invest. (1986) [Pubmed]
  20. Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Sérée, E., Villard, P.H., Pascussi, J.M., Pineau, T., Maurel, P., Nguyen, Q.B., Fallone, F., Martin, P.M., Champion, S., Lacarelle, B., Savouret, J.F., Barra, Y. Gastroenterology (2004) [Pubmed]
  21. Coronary heart disease, cancer, lipoproteins, and the effects of clofibrate: is enzyme induction a common link and are lipoproteins red herrings? Heller, R.F. Lancet (1981) [Pubmed]
  22. Matrical inclusions induced by clofibrate in hepatic microbodies of rats fed 2-acetylaminofluorene. Tsukada, H., Mochizuki, Y., Gotoh, M. J. Natl. Cancer Inst. (1975) [Pubmed]
  23. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. Hanley, K., Jiang, Y., Crumrine, D., Bass, N.M., Appel, R., Elias, P.M., Williams, M.L., Feingold, K.R. J. Clin. Invest. (1997) [Pubmed]
  24. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Miller, C.W., Ntambi, J.M. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  25. Physiological and x-ray studies of potential antisickling agents. Abraham, D.J., Perutz, M.F., Phillips, S.E. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  26. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Reddy, J.K., Goel, S.K., Nemali, M.R., Carrino, J.J., Laffler, T.G., Reddy, M.K., Sperbeck, S.J., Osumi, T., Hashimoto, T., Lalwani, N.D. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  27. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J., Latruffe, N. J. Biol. Chem. (1998) [Pubmed]
  28. Association of the kinesin motor KIF1A with the multimodular protein liprin-alpha. Shin, H., Wyszynski, M., Huh, K.H., Valtschanoff, J.G., Lee, J.R., Ko, J., Streuli, M., Weinberg, R.J., Sheng, M., Kim, E. J. Biol. Chem. (2003) [Pubmed]
  29. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. Ledwith, B.J., Pauley, C.J., Wagner, L.K., Rokos, C.L., Alberts, D.W., Manam, S. J. Biol. Chem. (1997) [Pubmed]
  30. Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Summerfield, J.A., Elias, E., Sherlock, S. Gastroenterology (1975) [Pubmed]
  31. Rapid purification of cytosolic epoxide hydrolase from normal and clofibrate-treated animals by affinity chromatography. Prestwich, G.D., Hammock, B.D. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  32. Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. Sundseth, S.S., Waxman, D.J. J. Biol. Chem. (1992) [Pubmed]
  33. Rat liver peroxisomes catalyze the beta oxidation of fatty acids. Lazarow, P.B. J. Biol. Chem. (1978) [Pubmed]
WikiGenes - Universities